Two biomarkers based on DNA methylation (DNAm) were strongly associated with a person’s risk for heart attack and stroke, according to new research led by Harvard T.H. Chan School of Public Health. The two biomarkers, known as GrimAgeAccel and DNAmRS, were also significantly associated with overall risk of premature death.
The study, led by CuiCui Wang, a research fellow in the Department of Environmental Health at Harvard T.H. Chan School of Public Health, was published December 4, 2020 in EBioMedicine. It identified five different DNAm-based biomarkers associated with aging and then analyzed these biomarkers in blood samples collected through two large cohort studies.
The researchers focused on determining how closely associated each biomarker was with premature death, heart attack, stroke, and cancer. The findings showed that none of the biomarkers was associated with cancer, but that several of them were strongly associated with premature death, heart attack, stroke.
From a public health perspective, the team noted, GrimAgeAccel was the valuable biomarker for assessing risk of death, heart attack, and stroke and could serve as a useful tool for identifying elderly people at elevated risk for such events.
Read the EBioMedicine study: DNA methylation-based biomarkers of age acceleration and all-cause death, myocardial infarction, stroke, and cancer in two cohorts: The NAS, and KORA F4